The UA Sprinkler Fitters Local 669 JATC – Notice of Privacy Incident
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro
GEARWRENCH Continues to Redefine Automotive Diagnostics with Powerful New Tools
Tampa General’s Innovation Week Returns with New Programming to Showcase Breakthroughs in Patient Care and Technology
New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships...
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product...
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the...
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune toleranceCHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma,...
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026...
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J.,...
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’...
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,...
MONTREAL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF)...
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and...
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan. 28, 2026...
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™...
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements...
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines...
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient...
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in...
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of...
